These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 14619529)

  • 1. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
    Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
    Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
    Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9].
    Takahashi Y; Mai M
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
    Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
    Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
    Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma.
    Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Casaldi V; Cavaliere F; Carlini M; Garofalo A; Rinaldi G
    Anticancer Res; 1993; 13(6B):2409-13. PubMed ID: 8135475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
    Li Y; Yang Y; Lu M; Shen L
    Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma.
    Ikeguchi M; Katano K; Saitou H; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1997; 44(15):866-71. PubMed ID: 9222706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
    Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
    Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
    Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.